— Know what they know.
Not Investment Advice

CBDL OTC

CBD Life Sciences Inc.
1W: +0.0% 1M: -50.0% 3M: -66.7% YTD: -50.0% 1Y: -83.3% 3Y: -100.0% 5Y: -100.0%
$0.00
-0.00 (-50.00%)
 
Weekly Expected Move ±70.3%
$-0 $0 $0 $0 $0
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 54 · $187697 mcap · Short 30% of daily vol

Balance Sheet Trends

Total Assets
$805K +98.0% ▲
5Y CAGR: +41.2%
Total Liabilities
$39K +172.5% ▲
5Y CAGR: -25.2%
Shareholders Equity
$767K +95.3% ▲
Cash & Investments
$332K +4963.3% ▲
5Y CAGR: +97.6%
Total Debt
$0 +0.0% ▲
Net Debt
-$332K -4963.3% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$1M$558$3K$7K$332K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$1M$558$3K$7K$332K
Net Receivables$0$0$0$0$216K
Inventory$0$8K$21K$32K$35K
Other Current Assets$0$169K$176K$204K$0
Total Current Assets$1M$178K$199K$243K$582K
Property, Plant & Equip.$152K$190K$89K$32K$0
Goodwill & Intangibles$100$100K$126K$110K$100K
Long-Term Investments$0$0$0$18K$118K
Other Non-Current Assets$139K$5K$5K$5K$5K
Total Non-Current Assets$291K$295K$220K$164K$223K
Total Assets$1M$473K$419K$407K$805K
— Liabilities —
Accounts Payable$0$0$0$0$33K
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$0$25K$14K$5K
Total Current Liabilities$0$0$25K$14K$39K
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$30K$0$0$0$0
Total Non-Current Liabilities$30K$0$0$0$0
Total Liabilities$30K$0$25K$14K$39K
— Equity —
Common Stock$4M$4M$4M$4M$5M
Retained Earnings-$14M-$14M-$15M-$15M-$15M
Accumulated OCI$0-$4M-$13K$0$0
Total Stockholders Equity$1M$473K$395K$393K$767K
Total Liabilities & Equity$1M$473K$419K$407K$805K
— Key Metrics —
Total Debt$0$0$0$0$0
Net Debt-$1M-$558-$3K-$7K-$332K
Total Investments$0$0$0$18K$118K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms